Phase 1
Completed N=64
A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
Kidney Failure, Chronic
Source: ClinicalTrials.gov NCT02144285 ↗
Enrolled (actual)
64
Serious AEs
1.6%
Results posted
Jan 2019
Primary outcomePrimary: Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Summary
The purpose of this study is to look at the tolerability and safety of LY3113593. Study doctors will see how safe it is and whether it produces side effects following a single injection into a vein or under the skin in healthy participants (Part A) and participants with chronic kidney disease treated with hemodialysis (Part B). The study will also measure how much of the study drug gets into the blood stream, how long it takes the body to get rid of the study drug and what effects the study drug has on the body.
This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition. For each participant, the study will last about 85 days, not including screening. Screening is required within 28 days prior to the start of the study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Pharmacokinetics: Maximum Concentration (Cmax) of LY3113593 |
559; 2070; 6330; 20000; 60800; 170000 | — |
| SECONDARY Pharmacokinetics: Area Under the Concentration Curve to Infinity (AUC (0-∞)) of LY3113593 |
55700; 280000; 1100000; 5240000; 17000000; 38300000 | — |
| SECONDARY Pharmacokinetics: Absolute Bioavailability of LY3113593 SC Versus IV Based on AUC Ratios |
7640000; 17000000 | — |
| SECONDARY Pharmacodynamics: Maximum Change From Baseline in Iron Parameter Profile of LY3113593 |
6.78; 4.12; 9.46; 8.38; 10.23; 13.5 | — |
| SECONDARY Pharmacodynamics: Maximum Absolute Change From Baseline in TSat Parameter Profile of LY3113593 |
11.00; 6.80; 14.80; 15.70; 12.80; 21.00 | — |
| SECONDARY Pharmacodynamics: Maximum Change From Baseline in Hemoglobin (Hb) Parameter Profile of LY3113593 |
0.269; 0.425; 0.123; 0.205; 0.780; 0.508 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy Participants:
- Healthy males or females
- Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter square (kg/m^2), inclusive at screening
- Participants Treated with Hemodialysis:
- Participants are males or females who have end-stage renal disease (ESRD) and have been receiving adequate maintenance hemodialysis (3 times weekly) for at least 12 weeks prior to screening
- Participants have a hemoglobin value greater than or equal to (≥)9.0 grams per deciliter (g/dL) and less than or equal to (≤)12.5 g/dL at screening
- Participants have a body mass index (BMI) of 18.5 to 45.0 kg/m^2, inclusive, at screening
- Both Populations:
- Male participants agree to use a reliable method of birth control and avoid donating sperm during the study and for 3 months following the dose of the investigational product
- Female participants must not be of child-bearing potential
Exclusion Criteria
- Healthy Participants:
- Participants that have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Participants that have used or intend to use over-the-counter or prescription medication, including herbal medications within 14 days prior to dosing
- Participants Treated with Hemodialysis:
- Participants that have a history of myocardial infarction, acute coronary syndrome, stroke or transient ischemic attacks within the prior 6 months
- Participants that have heart failure that results in dyspnea at rest or during minimal exercise
- Participants that have poorly controlled hypertension
- Participants that have a history of significant thrombotic disease, pulmonary hypertension, significant hematological disease or current liver disease, known hepatic or biliary abnormalities
- Participants that had a blood transfusion within the prior 12 weeks or an anticipated need for blood transfusion during the study
- Participants that have evidence of active peptic, duodenal, or esophageal ulcer disease or gastrointestinal bleeding within the prior 12 weeks
- Both Populations:
- Participants that have known allergies to related compounds or any components of the study drug or its formulation, clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions or history of significant atopy
- Participants that have participated, within the last 30 days (or 5 half-lives if long half life) in a clinical trial involving an investigational product
- Participants that have known or ongoing psychiatric disorders
Data sourced from ClinicalTrials.gov (NCT02144285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.